Retinoblastoma, Cr pediatric ocular malignant tumor is a potentially killing disease. It occurs
most commonly below 05 years of age, usually presents with leukocoria. Early detection
with prompt and accurate treatment is life saving as well as sight preserving. The management
of retinoblastoma has been changing over the past 04 decades. Enucleation and external beam
therapy used to be the favorite treatment in the distant past. Survival remained unpredictable for
quite a long time. But during the last 02 decades the treatment of the disease has revolutionized
through the introduction of different modes of chemotherapy. Chemo reduction with adjuvant
local therapy has received world wide acceptance. Survival now has reached almost 95% in the developed world, although the
developing countries still face miserable deaths resulting from retinoblastoma. There is still a ire need for accomplishing a complete
cure, in the case of each child suffering from retinoblastoma. Further research in this respect still goes on.
Dr. Muhammad Arif is assistant professor and head of Ophthalmology in KUST Institute of Medical Sciences Kohat. He is director Medical Education and
has series of publications on retinoblastoma in international and national journals of ophthalmology.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals